Premium
Cyclosporine pharmacokinetics in anti‐HCV+ patients
Author(s) -
Wolffenbüttel Luciano,
Poli Débora D,
Manfro Roberto C,
Gonçalves Luiz Felipe S
Publication year - 2004
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2004.00256.x
Subject(s) - medicine , pharmacokinetics , hemodialysis , kidney transplantation , gastroenterology , transplantation , dialysis , kidney , urology , area under the curve
Background: Cyclosporine (CsA) is a widely used immunosuppressive agent in kidney transplant patients. In Brazil, around 30% of patients awaiting kidney transplantation carry anti‐HCV antibodies. Previous observations suggest altered CsA pharmacokinetics in these patients. Methods: We conducted two pharmacokinetic studies. In the pre‐transplant (pre‐Tx) study, we examined 22 dialysis patients on chronic hemodialysis awaiting transplantation, 11 anti‐HCV+ [seven polymerase chain reaction (PCR)‐positive] matched against 11 controls. In the post‐transplant (post‐Tx) study, we enrolled 24 kidney allograft recipients – 10 anti‐HCV+ (six PCR‐positive), and 14 controls. In the first study, all patients received an 8‐mg/kg dose of CsA microemulsion (ME). Secondly, the dosage was indicated by the patient's medical team. Pharmacokinetic parameters were calculated from 13 blood samples (0–12 h postdose) by fluorescence polarization immunoassay with specific monoclonal antibodies. Results: In both studies, maximum concentration ( C max ), minimum concentration ( C min ) and area under the CsA time–concentration curve from 0 to 12 h ( AUC 0−12 ) were higher for anti‐HCV+ patients than for controls, but significantly so only for AUC 0−12 in the pre‐Tx study (42%; p < 0.05). When PCR‐positive patients were compared with controls, differences were amplified. In the pre‐Tx study, differences were 58%, 69%, and 91% higher in PCR‐positive patients for C max (p = 0.05), AUC 0−12 (p < 0.01), and C min (p < 0.01), respectively. In the post‐Tx study, results were 50% (p < 0.01) and 32% (p < 0.01) higher in PCR‐positive patients for C max and AUC 0−12 , respectively. In the pre‐Tx study, the impact of viremia was significantly higher in female patients. CsA trough levels remained higher along the first year post‐transplantation in viremic patients. Conclusions: Anti‐HCV+ patients, especially those with viremia, present altered CsA pharmacokinetics, with higher peak levels and drug exposure than controls.